Fresh analysis reveals that individuals who come off new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional lifestyle programs.
Research printed in a major medical journal shows that while overweight individuals often shed a large proportion of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such medications should be aware of the potential of fast weight regain when the medication is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment weight in about 18 months.
Comparing Approaches
The study, which examined dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
The team note that people who shed pounds through dieting typically have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors believe the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to appetite is no longer kept in check, making overeating much more probable."
A Lifelong Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, given the high risk of relapse, the treatment is often ongoing.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
Individuals who have discontinued the jabs report a intense resurgence of cravings.
"I experienced a trigger flipping and you're instantly starving," described a patient.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural modifications during treatment.
Significant Interest
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural changes.
